12:00 AM
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Surfaxin lucinactant regulatory update

Discovery Labs said it submitted a response to FDA's request for information to clarify aspects of the manufacturing process for Surfaxin lucinactant to prevent respiratory distress syndrome (RDS) in premature infants at high risk for RDS. The company expects the agency may take up to...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >